Bradley J. Bolzon PhD - 28 Jun 2021 Form 4 Insider Report for Monte Rosa Therapeutics, Inc. (GLUE)

Role: Director, 10%+ Owner
Signature: /s/ Ajim Tamboli, Attorney-in-Fact
Issuer symbol: GLUE
Transactions as of: 28 Jun 2021
Net transactions value: +$3,000,005
Form type: 4
Filing time: 30 Jun 2021, 17:05:14 UTC
Previous filing: 23 Jun 2021
Next filing: 21 Jul 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	GLUE	Common Stock	Conversion of derivative security		+6,515,869	+2300%		6,799,115	28 Jun 2021	By Versant Venture Capital VI, L.P.	F1, F2
transaction	GLUE	Common Stock	Conversion of derivative security		+1,940,043			1,940,043	28 Jun 2021	By Versant Vantage I, L.P.	F1, F3
transaction	GLUE	Common Stock	Purchase	$3,000,005	+157,895	+8.1%	$19.00	2,097,938	28 Jun 2021	By Versant Vantage I, L.P.	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	GLUE	Series A convertible preferred stock	Conversion of derivative security		-20,004,280	-100%		0	28 Jun 2021	Common Stock	5,666,131		By Versant Capital VI, L.P.	F1, F2
transaction	GLUE	Series B convertible preferred stock	Conversion of derivative security		-3,000,000	-100%		0	28 Jun 2021	Common Stock	849,738		By Versant Capital VI, L.P.	F1, F2
transaction	GLUE	Series B convertible preferred stock	Conversion of derivative security		-4,150,000	-100%		0	28 Jun 2021	Common Stock	1,175,470		By Versant Vantage I, L.P.	F1, F3
transaction	GLUE	Series C convertible preferred stock	Conversion of derivative security		-2,699,328	-100%		0	28 Jun 2021	Common Stock	764,573		By Versant Vantage I, L.P.	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date.
F2	Shares held by Versant Venture Capital VI, L.P. ("Versant VI"). Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
F3	Shares held by Versant Vantage I, L.P. ("Versant Vantage I"). Versant Vantage I GP, L.P. ("Versant Vantage I GP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP. The Reporting Person is a managing member of Versant Vantage I GP-GP, and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.